TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. disclosed the initial equity holdings of its new Chief Medical Officer, Marshall Richard Henry, as he became an executive officer effective June 29, 2026. The filing shows direct ownership of 30,000 shares of common stock, acquired before his appointment.

Henry also holds several employee stock options giving rights to purchase additional common shares. These include options linked to 60,000, 48,000, and 25,000 underlying common shares at exercise prices of $5.55, $4.96, and $4.01 per share, expiring between 2034 and 2035. Footnotes describe time-based vesting schedules for both restricted stock units and these option grants, contingent on his continued service with the company.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Marshall Richard Henry

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 25,000 shares (Direct, null); Common Stock — 30,000 shares (Direct, null)

Footnotes (1)

1. The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective June 29, 2026. Consists of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in four equal annual installments commencing on the one-year anniversary of the grant date of November 24, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of November 14, 2024 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of June 2, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

Key Figures

Direct common stock held: 30,000 shares Option underlying shares (grant 1): 60,000 shares Option underlying shares (grant 2): 48,000 shares +4 more

7 metrics

Direct common stock held 30,000 shares Total shares of common stock following transaction

Option underlying shares (grant 1) 60,000 shares Employee stock option, exercise price $5.55, expires 2035-11-24

Option underlying shares (grant 2) 48,000 shares Employee stock option, exercise price $4.96, expires 2035-07-07

Option underlying shares (grant 3) 25,000 shares Employee stock option, exercise price $4.01, expires 2034-11-14

Exercise price (grant 1) $5.55/share Employee Stock Option (right to buy) exercisable for common stock

Exercise price (grant 2) $4.96/share Employee Stock Option (right to buy) exercisable for common stock

Exercise price (grant 3) $4.01/share Employee Stock Option (right to buy) exercisable for common stock

Key Terms

restricted stock units, Employee Stock Option (right to buy), vesting commencement date, Chief Medical Officer, +1 more

5 terms

restricted stock units financial

"Consists of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Option (right to buy) financial

"security_title": "Employee Stock Option (right to buy)""

vesting commencement date financial

"the one-year anniversary of the vesting commencement date of November 14, 2024 (the "VCD")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Chief Medical Officer financial

""officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

beneficial ownership financial

"The Form 3 is an initial statement of beneficial ownership, listing holdings and option grants."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/29/2026 - 04:31 PM Accepted by SEC EDGAR 06/29/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Marshall Richard Henry

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2026

3. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	30,000(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(3)	11/14/2034	Common Stock	25,000(1)	$4.01	D
Employee Stock Option (right to buy)	(4)	07/07/2035	Common Stock	48,000(1)	$4.96	D
Employee Stock Option (right to buy)	(5)	11/24/2035	Common Stock	60,000(1)	$5.55	D

Explanation of Responses:

1. The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective June 29, 2026.

2. Consists of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in four equal annual installments commencing on the one-year anniversary of the grant date of November 24, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

3. One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of November 14, 2024 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

4. One-fourth (1/4th) of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of June 2, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

5. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing show about TLSI CMO Marshall Richard Henry’s holdings?

The Form 3 shows that Chief Medical Officer Marshall Richard Henry directly holds 30,000 shares of TriSalus Life Sciences common stock. These securities were acquired before he became an executive officer, and the filing records his starting equity position as of his appointment.

What stock options does Marshall Richard Henry hold in TriSalus (TLSI)?

Marshall Richard Henry holds employee stock options tied to 60,000, 48,000, and 25,000 underlying common shares. The respective exercise prices are $5.55, $4.96, and $4.01 per share, with expirations ranging from 2034 to 2035.

Are there restricted stock units (RSUs) disclosed for TLSI’s Chief Medical Officer?

Yes. A footnote states Henry received a restricted stock unit (RSU) award payable solely in common stock. The RSUs vest in four equal annual installments starting on the one-year anniversary of the November 24, 2025 grant date, subject to continued service.

Did Marshall Richard Henry buy or sell TLSI shares in this Form 3?

No buy or sell transactions are reported. The Form 3 is an initial statement of beneficial ownership, listing holdings and option grants as of his becoming an executive officer, with the transaction summary showing no purchases or sales.

How do the vesting terms work for the TLSI stock options held by Marshall Richard Henry?

Footnotes explain that for each option grant, one-fourth of the shares vest on the one-year anniversary of a specified vesting commencement date, and 1/36th of the remaining shares vest monthly thereafter, conditioned on his continuous service with TriSalus.

When did Marshall Richard Henry become an executive officer of TriSalus Life Sciences (TLSI)?

A footnote states that Henry was appointed as an executive officer of TriSalus Life Sciences effective June 29, 2026. The securities reported in the filing were acquired before this appointment and are now disclosed because of his new executive role.